Market Overview

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference


Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference

1 October 2020

LONDON, Silence Therapeutics plc (AIM: SLN) and (NASDAQ:SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that Mark Rothera, President and Chief Executive Officer, and Giles Campion, Head of R&D and Chief Medical Officer, will participate in a fireside chat at the Chardan Virtual 4th Annual Genetic Medicines Conference. The fireside chat will take place on Monday, October 5, 2020 at 14:00 EDT (19:00 BST).

A live webcast of the Company's fireside chat can be accessed via the Investors section of the Company's website at An archived replay of the webcasts will be available for 90 days on the Company's website after the conference.

For more information, please contact:

Silence Therapeutics plc
Gem Hopkins, Head of IR & Corporate Communications

Tel:  +1 (646) 637-3208
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence

Tel:  +44 (0)20 7597 5970
European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray

Tel: +44 (0) 20 3709 5700
Peter Vozzo
 Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit:

Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at